A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
CUPERTINO, Calif., June 28, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
CUPERTINO, Calif., May 26, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Met endpoints for safety and efficacy in 234 patients' clinical trial with Acute Schizophrenia or Schizoaffective DisorderMet primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for SchizophreniaMitigated positive symptoms and...
-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market- -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- CUPERTINO, Calif., March 22, 2021 -- Reviva Pharmaceuticals...
CUPERTINO, Calif., March 11, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
CUPERTINO, Calif., March 04, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva") today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing...
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 -- Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation ("Reviva Holdings"), as the successor to Tenzing Acquisition Corp., a special...